Chae Han
About Chae Han
Chae Han serves as the Executive Director of Antibody Drug Substance Development & Manufacturing at Arcus Biosciences, where he focuses on the commercialization of antibodies for cancer treatment. He has extensive experience in the field, having held positions at Baxter Healthcare, Amgen, and Allergan, and holds a Ph.D. in Biochemical Engineering from North Carolina State University.
Current Role at Arcus Biosciences
Chae Han serves as the Executive Director of Antibody Drug Substance Development & Manufacturing at Arcus Biosciences. In this role, Han is responsible for overseeing the commercialization of antibodies specifically used in cancer treatment. Since joining Arcus Biosciences in 2023, Han has focused on enhancing the development and manufacturing processes of antibody drug substances. This position builds on previous experience in the field, including a role as Sr. Director of Antibody Development and Manufacturing from 2021 to 2023.
Previous Experience in Biopharmaceuticals
Chae Han has extensive experience in the biopharmaceutical industry, having worked at several prominent organizations. Prior to joining Arcus Biosciences, Han spent 15 years at Amgen as a Principal Scientist from 2006 to 2021. Earlier in their career, Han worked at Baxter Healthcare as a Research Scientist from 2003 to 2006 and at Allergan as a Scientist from 2000 to 2003. This diverse background has contributed to Han's expertise in antibody development and manufacturing.
Educational Background
Chae Han holds a Bachelor of Science (BS) in Chemical Engineering from The University of Texas at Austin. Additionally, Han earned a Doctor of Philosophy (Ph.D.) in Biochemical Engineering from North Carolina State University. This educational foundation has equipped Han with the technical knowledge necessary for a successful career in the biopharmaceutical industry.
Expertise in Antibody Drug Development
In the role of Executive Director at Arcus Biosciences, Chae Han oversees tech transfer processes in antibody drug substance development. This expertise is critical for ensuring the successful transition of antibody products from development to commercialization. Han's focus on cancer treatment antibodies highlights a commitment to advancing therapeutic options in oncology.